BNET Industries
Market Cap:$3.6B
Last Fiscal Year Sales:$1.8B
- Public
- US
Dow Jones Description
Perrigo Company, established in 1887, is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the worlds largest manufacturer of OTC pharmaceutical products for the store brand market. The Companys primary markets and locations of manufacturing and logistics operations are the United States (U.S.), Israel, Mexico and the United Kingdom (U.K.). See Note 17 to the Companys consolidated financial statements for further information. Perrigo Company operates through several wholly owned subsidiaries. In the U.S., its operations are conducted primarily through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., Perrigo Holland, Inc. (formerly J.B. Laboratories, Inc.) and Perrigo Florida, Inc. (formerly Unico Holdings, Inc.). Outside the U.S., its operations are conducted primarily through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Brunel Pharma Limited (formerly Brunel Healthcare Ltd.) and Galpharm Healthcare Ltd. As used herein, references to the Company means Perrigo Company, its subsidiaries and all predecessors of Perrigo Company and its subsidiaries.
Number of Employees 6,200
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Business headlines: Saab, Swedes look for buyer
-
Flu, economy boost drug maker Perrigo
-
Arkin investment NeurogesX gets FDA approval for patch: Mori Arkin owns 15% of the US...
-
Todays Zacks Rank Growth and Income Buy: Ross Stores, Inc.
-
NPI Watch - Nov. 2, 2009 - Editorial: Dr. Joshua Sharfstein at the Annual...
-
Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
-
Bank of America Maintains a 'Buy' on Perrigo Company PRGO; Raises PT
-
UPDATE 1-Perrigo buys KV Pharma filing for generic acne gel
-
BUYINS.NET: 50.78% Of All NASDAQ Trading Tuesday Was Short Selling. BPSG, SHAW, ELOS, EXEL, PRGO,...
-
Expansion anticipated as Perrigo enters new fiscal year
-
Perrigo gears up for cough/cold season
-
Perrigo posts $144M profit
News & Analysis
Filter by
finance and perrigo co. - All News and Analysis
Earnings Preview: Perrigo
Perrigo PRGO is expected to report Q1 earnings before market open Thursday, November 6, with a conference call scheduled for 10:00 am ET. Guidance Analysts are looking for a profit of 43c on revenue of $496M. The consensus range is 40c to 46c for EPS, and revenue of $479M to...
Zacks Releases Four Powerful "Buy" Stocks: Diamond Foods, Perrigo Co., Albany Molecular Research and Shanda Interactive Entertainment
CHICAGO -- Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value....
SCOLR Pharma, Inc. Reports Third Quarter 2006 Financial Results
BELLEVUE, Wash. -- SCOLR Pharma, Inc. (AMEX: DDD) today reported financial results for the three and nine months ended September 30, 2006. Revenues for the three months ended September 30, 2006, increased significantly to $1,069,897 compared to $205,764 for the comparable period in 2005. For the nine months ended September...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes

